Chembio Diagnostic Systems, Inc. (NASDAQ: CEMI) develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases. Founded in 1985 to develop products used in diagnostic laboratories, Chembio entered the POC testing field in the late 1990s and, in 2002, focused its business to participate in the emerging global need and opportunity for rapid HIV tests. The Company became public in 2004 and is now a leading employer on Long Island, New York, with approximately 200 employees. Revenues during 2013 approached $30MM.  More »



Recent Releases

Dec 21, 2017
Chembio Diagnostics Announces Completion of U.S. Clinical Trial Evaluating DPP® HIV-Syphilis System

Dec 20, 2017
Chembio Diagnostics Announces Appointment of Neil A. Goldman as Chief Financial Officer

View all releases »

Financial Reports

Q3 2017 Quarterly Report
Filed on Nov 8, 2017


Q2 2017 Quarterly Report
Filed on Aug 9, 2017


Q1 2017 Quarterly Report
Filed on May 9, 2017


2016 Annual Report
Filed on Mar 7, 2017


Q3 2016 Quarterly Report
Filed on Nov 10, 2016


View all filings »

Featured Presentations

January 2018 Investor Presentation

January 2018 Fact Sheet

Print Print Page  |  Email Email Page